Two neurostructural subtypes: results of machine learning on brain images from 4,291 individuals with schizophrenia.
ENIGMA
artificial intelligence
brain gray matter
schizophrenia
structural MRI
subtype
Journal
medRxiv : the preprint server for health sciences
Titre abrégé: medRxiv
Pays: United States
ID NLM: 101767986
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
pubmed:
24
10
2023
medline:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
Machine learning can be used to define subtypes of psychiatric conditions based on shared clinical and biological foundations, presenting a crucial step toward establishing biologically based subtypes of mental disorders. With the goal of identifying subtypes of disease progression in schizophrenia, here we analyzed cross-sectional brain structural magnetic resonance imaging (MRI) data from 4,291 individuals with schizophrenia (1,709 females, age=32.5 years±11.9) and 7,078 healthy controls (3,461 females, age=33.0 years±12.7) pooled across 41 international cohorts from the ENIGMA Schizophrenia Working Group, non-ENIGMA cohorts and public datasets. Using a machine learning approach known as Subtype and Stage Inference (SuStaIn), we implemented a brain imaging-driven classification that identifies two distinct neurostructural subgroups by mapping the spatial and temporal trajectory of gray matter (GM) loss in schizophrenia. Subgroup 1 (n=2,622) was characterized by an early cortical-predominant loss (ECL) with enlarged striatum, whereas subgroup 2 (n=1,600) displayed an early subcortical-predominant loss (ESL) in the hippocampus, amygdala, thalamus, brain stem and striatum. These reconstructed trajectories suggest that the GM volume reduction originates in the Broca's area/adjacent fronto-insular cortex for ECL and in the hippocampus/adjacent medial temporal structures for ESL. With longer disease duration, the ECL subtype exhibited a gradual worsening of negative symptoms and depression/anxiety, and less of a decline in positive symptoms. We confirmed the reproducibility of these imaging-based subtypes across various sample sites, independent of macroeconomic and ethnic factors that differed across these geographic locations, which include Europe, North America and East Asia. These findings underscore the presence of distinct pathobiological foundations underlying schizophrenia. This new imaging-based taxonomy holds the potential to identify a more homogeneous sub-population of individuals with shared neurobiological attributes, thereby suggesting the viability of redefining existing disorder constructs based on biological factors.
Identifiants
pubmed: 37873296
doi: 10.1101/2023.10.11.23296862
pmc: PMC10593004
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : CSRD VA
ID : I01 CX000227
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH097196
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH056584
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH094524
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH106324
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH084803
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH121246
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH108150
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH109977
Pays : United States
Organisme : NCRR NIH HHS
ID : P20 RR021938
Pays : United States
Organisme : NCRR NIH HHS
ID : U24 RR021992
Pays : United States
Déclaration de conflit d'intérêts
Competing Interests Statement Lena Palaniyappan reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited UK and the Canadian Psychiatric Association; book royalties from Oxford University Press; and investigator-initiated educational grants from Sunovion, Janssen Canada and Otsuka Canada, outside the submitted work. Tilo Kircher received unrestricted educational grants from Servier, Janssen, Recordati, Aristo, Otsuka, neuraxpharm. Philipp Homan has received grants and honoraria from Novartis, Lundbeck, Mepha, Janssen, Boehringer Ingelheim, Neurolite outside of this work. Ole A. Andreassen is a consultant to Cortechs.ai and received speakers honorarium from Lundbeck, Janssen, Sunovion. These interests played no role in the research reported here. Other authors disclose no conflict of interest.
Références
JAMA Psychiatry. 2020 Feb 1;77(2):201-210
pubmed: 31664453
Nat Med. 2022 Jan;28(1):31-38
pubmed: 35058619
J Nerv Ment Dis. 1994 Nov;182(11):631-8
pubmed: 7964671
Neuroimage. 2018 Dec;183:314-326
pubmed: 30121337
PLoS One. 2022 Dec 16;17(12):e0276975
pubmed: 36525414
J Psychiatry Neurosci. 2012 Jan;37(1):17-27
pubmed: 21693094
Lancet. 2018 Jun 23;391(10139):2476
pubmed: 29976453
Mol Psychiatry. 2021 Apr;26(4):1310-1320
pubmed: 31471576
Front Hum Neurosci. 2012 May 23;6:137
pubmed: 22654746
JAMA Psychiatry. 2019 Jul 1;76(7):739-748
pubmed: 30969333
Br J Psychiatry. 2014 Jul;205(1):1-3
pubmed: 24986384
Lancet. 2003 Jan 25;361(9354):281-8
pubmed: 12559861
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:254-262
pubmed: 30248379
Neuroimage. 2015 Jul 15;115:117-37
pubmed: 25936807
Neuroimage. 2017 Jul 15;155:370-382
pubmed: 28479476
Neurology. 2021 Aug 31;97(9):e941-e952
pubmed: 34158384
Schizophr Bull. 2013 Jul;39(4):751-3
pubmed: 23674819
Mol Psychiatry. 2016 Apr;21(4):585
pubmed: 26283641
Mol Psychiatry. 2023 Aug 29;:
pubmed: 37644174
J Psychiatr Brain Sci. 2020;5:
pubmed: 32258424
Brain. 2020 Mar 1;143(3):1027-1038
pubmed: 32103250
Mol Psychiatry. 2023 May;28(5):1843-1856
pubmed: 37041418
Mol Psychiatry. 2016 Apr;21(4):547-53
pubmed: 26033243
Biol Psychiatry. 2020 Feb 1;87(3):215-224
pubmed: 31561858
Schizophr Bull. 2018 Aug 20;44(5):1060-1069
pubmed: 29529270
Neuroimage. 2016 Jan 1;124(Pt B):1196-1201
pubmed: 26087378
Brain Stimul. 2019 Mar - Apr;12(2):319-328
pubmed: 30473477
Schizophr Bull. 2021 Apr 29;47(3):849-863
pubmed: 33257954
Nat Commun. 2021 Dec 3;12(1):7065
pubmed: 34862382
Schizophr Bull. 1987;13(2):261-76
pubmed: 3616518
Neuron. 2019 Jul 17;103(2):203-216.e8
pubmed: 31174959
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2400-9
pubmed: 23729812
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11650-5
pubmed: 11573002
Lancet Digit Health. 2020 Sep;2(9):e486-e488
pubmed: 33328116
Sci Data. 2016 Dec 06;3:160110
pubmed: 27922632
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Med Image Anal. 2022 Jan;75:102304
pubmed: 34818611
Schizophr Res. 1997 Dec 19;28(2-3):127-41
pubmed: 9468348
Neuroimage. 2016 Jan 1;124(Pt B):1074-1079
pubmed: 26364863
Mol Psychiatry. 2023 Aug 4;:
pubmed: 37537281
JAMA Psychiatry. 2015 Apr;72(4):316-24
pubmed: 25651194
Curr Neuropharmacol. 2022;20(6):1241-1252
pubmed: 34370638
World Psychiatry. 2020 Feb;19(1):15-33
pubmed: 31922684
Arch Gen Psychiatry. 2011 Feb;68(2):128-37
pubmed: 21300943
Nat Commun. 2018 Oct 15;9(1):4273
pubmed: 30323170
Neuroimage. 2020 Mar;208:116450
pubmed: 31821869
Br J Psychiatry. 2006 Jun;188:510-8
pubmed: 16738340
Schizophr Bull. 2021 Mar 16;47(2):562-574
pubmed: 32926141
Mol Psychiatry. 2016 Aug;21(8):1090-8
pubmed: 26194183
JAMA Psychiatry. 2018 Nov 1;75(11):1146-1155
pubmed: 30304337
Radiology. 2018 May;287(2):729
pubmed: 29668409
Neuroimage. 2020 Feb 1;206:116189
pubmed: 31521825
Cereb Cortex. 2009 May;19(5):1107-23
pubmed: 18842668
Sci Data. 2021 Aug 30;8(1):227
pubmed: 34462444
JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111
pubmed: 28973084
Neuroimage. 2015 Jun;113:184-95
pubmed: 25776214
JAMA Psychiatry. 2016 Feb;73(2):113-20
pubmed: 26719911
Mol Psychiatry. 2020 Apr;25(4):883-895
pubmed: 31780770
Schizophr Bull. 2021 Jul 8;47(4):1130-1140
pubmed: 33543752
Neuroinformatics. 2013 Jul;11(3):367-88
pubmed: 23760817
Mol Psychiatry. 2021 Nov;26(11):6926-6936
pubmed: 34588622
Neuropsychopharmacology. 2023 Jan;48(1):151-167
pubmed: 36056106
Biol Psychiatry. 2018 Nov 1;84(9):644-654
pubmed: 29960671
Lancet Psychiatry. 2016 May;3(5):451-63
pubmed: 26948188
Nat Med. 2021 May;27(5):871-881
pubmed: 33927414
Neuroimage. 2016 Jan 1;124(Pt B):1131-1136
pubmed: 26032888